Skip to content

Effects of silicone oil duration time on retinal choroidal structure, blood flow and intraocular fluid in patients with rhegmatogenous retinal detachment

Effects of silicone oil duration time on retinal choroidal structure, blood flow and intraocular fluid in patients with rhegmatogenous retinal detachment

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059077
Enrollment
Unknown
Registered
2022-04-24
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhegmatogenous retinal detachment

Interventions

Experimental group:Silicone oil removal in 2 months
Control group:Oil extraction time in 4 months

Sponsors

Xuzhou First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Voluntary participation in the study and good compliance; 2. Patients with primary rhegmatogenous retinal detachment older than 18 years old and involving macular fovea; 3. Off-grid time <= 2 weeks; 4. Patients who are in good general condition and can tolerate the operation; 5. Patients who are judged to need ciliary body pars plana vitrectomy (PPV) + so filling.

Exclusion criteria

Exclusion criteria: 1. High refractive error (spherical equivalent greater than 6), high myopia (axial length = 26.0 mm) and inter ocular axial length difference greater than 0.3 mm were excluded; 2. Other accompanying eye diseases (diabetic retinopathy, glaucoma, age-related macular degeneration, uveitis, retinal vascular disease or retina of any eye); 3. Postoperative complications (re detachment, proliferative vitreoretinopathy, intraocular pressure higher than 21 mmHg or vitreous hemorrhage); 4. History of previous intraocular surgery; 5. the other eye of the patient did not carry out EDI-OCT and OCTA examination, or EDI-OCT and OCTA examination showed that the scanning quality was poor (image quality below 6 points), measurement error (such as segmentation error, alignment error or fixed error) or artifact (defocus, blink, or motion artifact); 6. Patients who are participating in other clinical trials; The researchers believe that other reasons are not suitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
Glutamate;Methyl aspartate receptor;Interleukin-6;Interleukin-8;Interleukin-10;Interleukin-12;Vascular endothelial growth factor;Placental growth factor;Tumor necrosis factor-a;Total nitric oxide;Malondialdehyde;Total antioxidant;Glutathione;Choroidal vascular index;Subfoveal choroidal thickness;Retinal nerve fiber layer thickness;Ganglion cell layer thickness;Thickness of each layer from plexiform layer to photoreceptor layer in retina;Reset rate;Best corrected visual acuity;Magnesium ion;Calcium ion;Potassium ion;Sodium ion;Chloride ion;

Secondary

MeasureTime frame
Optic disc blood flow density;Macular blood flow density;Emulsification degree of silicone oil;Measure the deformation degree of visual object with M-CHARTS table;Multifocal ERG;

Countries

China

Contacts

Public ContactHaiyang Liu

Xuzhou First People's Hospital

liuhaiyang86@126.com+86 13685167216

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026